MTOR and osteosarcoma: To address these possibilities, as well as the potential involvement of NRF2 in the SFN-mediated inhibition of mTOR, in this study we used the human osteosarcoma cell line U2OS and its CRISPR/Cas9-generated NRF2-knockout counterpart.